Zobrazeno 1 - 10
of 46
pro vyhledávání: '"Marissa F Dockendorf"'
Autor:
Ramesh Boinpally, Marleen Depré, Griet Van Lancker, Marissa F Dockendorf, Phung Bondiskey, Jean-Francois Denef, Tom Reynders, Catherine Zhou Matthews, K Chris Min, Jialin Xu, Joel M Trugman, Jan de Hoon
Publikováno v:
Cephalalgia Reports, Vol 6 (2023)
Background/Hypothesis: Atogepant, an oral calcitonin gene-related peptide receptor antagonist, is approved for the preventive treatment of migraine in adults. This manuscript characterizes the safety, tolerability, pharmacokinetics and pharmacokineti
Externí odkaz:
https://doaj.org/article/5322ddc1d94045a5bbfac12682cc3682
Autor:
Ashley Polhemus, Jan Novak, Shazmin Majid, Sara Simblett, Daniel Morris, Stuart Bruce, Patrick Burke, Marissa F Dockendorf, Gergely Temesi, Til Wykes
Publikováno v:
JMIR Mental Health, Vol 9, Iss 4, p e25249 (2022)
BackgroundRemote measurement technologies (RMT) such as mobile health devices and apps are increasingly used by those living with chronic neurological and mental health conditions. RMT enables real-world data collection and regular feedback, providin
Externí odkaz:
https://doaj.org/article/26c526232b6d469bb3248ba5ed66a968
Autor:
Anzar Abbas, Bryan J Hansen, Vidya Koesmahargyo, Vijay Yadav, Paul J Rosenfield, Omkar Patil, Marissa F Dockendorf, Matthew Moyer, Lisa A Shipley, M Mercedez Perez-Rodriguez, Isaac R Galatzer-Levy
Publikováno v:
JMIR Formative Research, Vol 6, Iss 1, p e26276 (2022)
BackgroundMachine learning–based facial and vocal measurements have demonstrated relationships with schizophrenia diagnosis and severity. Demonstrating utility and validity of remote and automated assessments conducted outside of controlled experim
Externí odkaz:
https://doaj.org/article/3121097e50374e5ea7adf31f2faabf76
Autor:
Abhijeet Jakate, Ramesh Boinpally, Matthew Butler, Wendy Ankrom, Marissa F Dockendorf, Antonia Periclou
Publikováno v:
Cephalalgia Reports, Vol 4 (2021)
Background: Ubrogepant is metabolized by cytochrome P450 3A4 (CYP3A4) and is a P-glycoprotein (P-gp) substrate. Objective: To assess effects of multiple-dose moderate-strong CYP3A4 and strong P-gp inhibitors and inducers on ubrogepant pharmacokinetic
Externí odkaz:
https://doaj.org/article/6b11227d7cf84f469b08f823316b742f
Autor:
Wendy Ankrom, Phung Bondiskey, Chi‐Chung Li, John Palcza, Wen Liu, Marissa F. Dockendorf, Catherine Matthews, Deborah Panebianco, Tom Reynders, John A. Wagner, Abhijeet Jakate, Sofie Mesens, Walter K. Kraft, Eugene E. Marcantonio
Publikováno v:
Clinical and Translational Science, Vol 13, Iss 3, Pp 462-472 (2020)
Ubrogepant is a novel, oral calcitonin gene‐related peptide (CGRP) receptor antagonist intended for the acute treatment of migraine attacks. Ubrogepant has a chemical structure distinct from previous small‐molecule CGRP receptor antagonists that
Externí odkaz:
https://doaj.org/article/574f65b94dbe404bae99bc9aaa2303f2
Autor:
Mark Forman, John Palcza, Jack Tseng, Julie A. Stone, Brittany Walker, Dennis Swearingen, Matthew D. Troyer, Marissa F. Dockendorf
Publikováno v:
Clinical and Translational Science, Vol 12, Iss 5, Pp 545-555 (2019)
β‐site amyloid precursor protein‐cleaving enzyme 1 (BACE1) is required for the production of β‐amyloid peptides, which are implicated in the etiology of Alzheimer's disease. The safety and pharmacokinetics of the BACE1 inhibitor verubecestat
Externí odkaz:
https://doaj.org/article/d5a82e2a471d464587738eee563b31d1
Autor:
Marissa F, Dockendorf, David, Jaworowicz, Rebecca, Humphrey, Melanie, Anderson, Sheila, Breidinger, Lei, Ma, Theresa, Taylor, Nicole, Dupre, Christopher, Jones, Christine, Furtek, Bhavna, Kantesaria, Kevin P, Bateman, Eric, Woolf, Michael F, Egan, Julie A, Stone
Publikováno v:
The AAPS Journal. 24
In-clinic venous dried blood spot (DBS) pharmacokinetic (PK) sampling was incorporated into two phase 3 studies of verubecestat for Alzheimer's disease (EPOCH [NCT01739348] and APECS [NCT01953601]), as a potential alternative to plasma PK sampling. I
Autor:
Ashley Polhemus, Sara Simblett, Erin Dawe Lane, Benjamin Elliott, Sagar Jilka, Esther Negbenose, Patrick Burke, Janice Weyer, Jan Novak, Marissa F. Dockendorf, Gergely Temesi, Til Wykes
Publikováno v:
Multiple Sclerosis and Related Disorders. 69:104435
Mobile health applications (apps) are promising condition self-management tools for people living with multiple sclerosis (MS). However, most existing apps do not include health tracking features. This gap has been raised as a priority research topic
Autor:
Marissa F. Dockendorf, Kevin P. Bateman, Bryan J. Hansen, Matthew Moyer, Jyoti Shah, Lisa A. Shipley
Publikováno v:
Clinical and Translational Science, Vol 14, Iss 2, Pp 445-459 (2021)
Clinical and Translational Science
Clinical and Translational Science
The rapidly advancing field of digital health technologies provides a great opportunity to radically transform the way clinical trials are conducted and to shift the clinical trial paradigm from a site‐centric to a patient‐centric model. Merck’
Autor:
Jialin Xu, Catherine Z. Matthews, Ramesh Boinpally, Wen Liu, Lori A. Mixson, Francheska Colon-Gonzalez, Marissa F. Dockendorf, Deborah Panebianco, Phung Bondiskey, Walter K. Kraft, K Chris Min
Publikováno v:
Clinical and Translational Science
Clinical and Translational Science, Vol 14, Iss 2, Pp 599-605 (2021)
Clinical and Translational Science, Vol 14, Iss 2, Pp 599-605 (2021)
Atogepant is a potent, selective, oral calcitonin gene–related peptide (CGRP) receptor antagonist in development for migraine prevention. The chemical structure of atogepant is distinct from previous CGRP receptor antagonists, which were associated